Loading…
Supporting the use of adjuvant radiotherapy in recurrent pleomorphic adenoma of the parotid
The use of adjuvant radiotherapy remains controversial in the treatment of recurrent pleomorphic adenomas. The aim of this study was to provide the highest level of evidence possible by performing a systematic review and meta-analysis of the literature. We searched the English-language literature be...
Saved in:
| Published in: | Acta oto-laryngologica 2021-10, Vol.141 (10), p.971-976 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3 |
| container_end_page | 976 |
| container_issue | 10 |
| container_start_page | 971 |
| container_title | Acta oto-laryngologica |
| container_volume | 141 |
| creator | Hintze, Justin M. O'Duffy, Fergal White-Gibson, Ailbhe O'Neill, Paul Kinsella, John Timon, Conrad Lennon, Paul |
| description | The use of adjuvant radiotherapy remains controversial in the treatment of recurrent pleomorphic adenomas.
The aim of this study was to provide the highest level of evidence possible by performing a systematic review and meta-analysis of the literature.
We searched the English-language literature between 1985 and 2019.Inclusion criteria included any study on the treatment and outcome of recurrent pleomorphic adenomas. Exclusion criteria included the use of radiotherapy for residual tumors, case reports, and pleomorphic adenomas not arising from the parotid.
A total of 522 abstracts were studied, data analyzed from 14 studies, on a total of 697 patients. When the data werepooled, the overall risk of further recurrence was 21%. In studies where surgery alone was undertaken this increased to 26% and decreased to 10% in those receiving adjuvant radiotherapy (p = .000). There were 21 recurrences in 159 patients in the radiotherapy group, and 151 recurrences out of 538 patients in the surgery group (p |
| doi_str_mv | 10.1080/00016489.2021.1980226 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34622733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580694666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouq7-BKVHL13z1TS5KeIXCB7Uk4eQpolG2qZOWmX_vS27evQ0DPO878CD0AnBK4IlPscYE8GlWlFMyYooiSkVO2hBREFySguyixYzk8_QATpM6WNelSz20QHjgtKSsQV6fRr7PsIQurdseHfZmFwWfWbqj_HLdEMGpg5xOoDp11noMnB2BHDTpW9cbCP078FOuOtia-bkXNIbiEOoj9CeN01yx9u5RC83189Xd_nD4-391eVDbjlhQ04s4QI767mvrGASE2oVK5QtfW2tZMpVEntZcEVwqaqyKmrJuKqksyUV3LAlOtv09hA_R5cG3YZkXdOYzsUxaVpILBQXQkxosUEtxJTAed1DaA2sNcF69qp_verZq956nXKn2xdj1br6L_UrcgIuNkDofITWfEdoaj2YdRPBg-lsSJr9_-MHYgqH4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580694666</pqid></control><display><type>article</type><title>Supporting the use of adjuvant radiotherapy in recurrent pleomorphic adenoma of the parotid</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Hintze, Justin M. ; O'Duffy, Fergal ; White-Gibson, Ailbhe ; O'Neill, Paul ; Kinsella, John ; Timon, Conrad ; Lennon, Paul</creator><creatorcontrib>Hintze, Justin M. ; O'Duffy, Fergal ; White-Gibson, Ailbhe ; O'Neill, Paul ; Kinsella, John ; Timon, Conrad ; Lennon, Paul</creatorcontrib><description>The use of adjuvant radiotherapy remains controversial in the treatment of recurrent pleomorphic adenomas.
The aim of this study was to provide the highest level of evidence possible by performing a systematic review and meta-analysis of the literature.
We searched the English-language literature between 1985 and 2019.Inclusion criteria included any study on the treatment and outcome of recurrent pleomorphic adenomas. Exclusion criteria included the use of radiotherapy for residual tumors, case reports, and pleomorphic adenomas not arising from the parotid.
A total of 522 abstracts were studied, data analyzed from 14 studies, on a total of 697 patients. When the data werepooled, the overall risk of further recurrence was 21%. In studies where surgery alone was undertaken this increased to 26% and decreased to 10% in those receiving adjuvant radiotherapy (p = .000). There were 21 recurrences in 159 patients in the radiotherapy group, and 151 recurrences out of 538 patients in the surgery group (p < .0001).
These data support the use of radiotherapy to decrease the risk of re-recurrence in recurrent pleomorphic adenoma.
This study is the highest level of evidence currently available in guiding management of recurrent pleomorphic adenoma.</description><identifier>ISSN: 0001-6489</identifier><identifier>EISSN: 1651-2251</identifier><identifier>DOI: 10.1080/00016489.2021.1980226</identifier><identifier>PMID: 34622733</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Adenoma, Pleomorphic - therapy ; Humans ; meta-analysis ; Neoplasm Recurrence, Local - therapy ; Parotid Neoplasms - therapy ; Pleomorphic adenoma ; radiotherapy ; Radiotherapy, Adjuvant ; recurrent ; Secondary Prevention</subject><ispartof>Acta oto-laryngologica, 2021-10, Vol.141 (10), p.971-976</ispartof><rights>2021 Acta Oto-Laryngologica AB (Ltd) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3</citedby><cites>FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3</cites><orcidid>0000-0002-7837-4032</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34622733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hintze, Justin M.</creatorcontrib><creatorcontrib>O'Duffy, Fergal</creatorcontrib><creatorcontrib>White-Gibson, Ailbhe</creatorcontrib><creatorcontrib>O'Neill, Paul</creatorcontrib><creatorcontrib>Kinsella, John</creatorcontrib><creatorcontrib>Timon, Conrad</creatorcontrib><creatorcontrib>Lennon, Paul</creatorcontrib><title>Supporting the use of adjuvant radiotherapy in recurrent pleomorphic adenoma of the parotid</title><title>Acta oto-laryngologica</title><addtitle>Acta Otolaryngol</addtitle><description>The use of adjuvant radiotherapy remains controversial in the treatment of recurrent pleomorphic adenomas.
The aim of this study was to provide the highest level of evidence possible by performing a systematic review and meta-analysis of the literature.
We searched the English-language literature between 1985 and 2019.Inclusion criteria included any study on the treatment and outcome of recurrent pleomorphic adenomas. Exclusion criteria included the use of radiotherapy for residual tumors, case reports, and pleomorphic adenomas not arising from the parotid.
A total of 522 abstracts were studied, data analyzed from 14 studies, on a total of 697 patients. When the data werepooled, the overall risk of further recurrence was 21%. In studies where surgery alone was undertaken this increased to 26% and decreased to 10% in those receiving adjuvant radiotherapy (p = .000). There were 21 recurrences in 159 patients in the radiotherapy group, and 151 recurrences out of 538 patients in the surgery group (p < .0001).
These data support the use of radiotherapy to decrease the risk of re-recurrence in recurrent pleomorphic adenoma.
This study is the highest level of evidence currently available in guiding management of recurrent pleomorphic adenoma.</description><subject>Adenoma, Pleomorphic - therapy</subject><subject>Humans</subject><subject>meta-analysis</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Parotid Neoplasms - therapy</subject><subject>Pleomorphic adenoma</subject><subject>radiotherapy</subject><subject>Radiotherapy, Adjuvant</subject><subject>recurrent</subject><subject>Secondary Prevention</subject><issn>0001-6489</issn><issn>1651-2251</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMouq7-BKVHL13z1TS5KeIXCB7Uk4eQpolG2qZOWmX_vS27evQ0DPO878CD0AnBK4IlPscYE8GlWlFMyYooiSkVO2hBREFySguyixYzk8_QATpM6WNelSz20QHjgtKSsQV6fRr7PsIQurdseHfZmFwWfWbqj_HLdEMGpg5xOoDp11noMnB2BHDTpW9cbCP078FOuOtia-bkXNIbiEOoj9CeN01yx9u5RC83189Xd_nD4-391eVDbjlhQ04s4QI767mvrGASE2oVK5QtfW2tZMpVEntZcEVwqaqyKmrJuKqksyUV3LAlOtv09hA_R5cG3YZkXdOYzsUxaVpILBQXQkxosUEtxJTAed1DaA2sNcF69qp_verZq956nXKn2xdj1br6L_UrcgIuNkDofITWfEdoaj2YdRPBg-lsSJr9_-MHYgqH4w</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Hintze, Justin M.</creator><creator>O'Duffy, Fergal</creator><creator>White-Gibson, Ailbhe</creator><creator>O'Neill, Paul</creator><creator>Kinsella, John</creator><creator>Timon, Conrad</creator><creator>Lennon, Paul</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7837-4032</orcidid></search><sort><creationdate>20211001</creationdate><title>Supporting the use of adjuvant radiotherapy in recurrent pleomorphic adenoma of the parotid</title><author>Hintze, Justin M. ; O'Duffy, Fergal ; White-Gibson, Ailbhe ; O'Neill, Paul ; Kinsella, John ; Timon, Conrad ; Lennon, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoma, Pleomorphic - therapy</topic><topic>Humans</topic><topic>meta-analysis</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Parotid Neoplasms - therapy</topic><topic>Pleomorphic adenoma</topic><topic>radiotherapy</topic><topic>Radiotherapy, Adjuvant</topic><topic>recurrent</topic><topic>Secondary Prevention</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hintze, Justin M.</creatorcontrib><creatorcontrib>O'Duffy, Fergal</creatorcontrib><creatorcontrib>White-Gibson, Ailbhe</creatorcontrib><creatorcontrib>O'Neill, Paul</creatorcontrib><creatorcontrib>Kinsella, John</creatorcontrib><creatorcontrib>Timon, Conrad</creatorcontrib><creatorcontrib>Lennon, Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta oto-laryngologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hintze, Justin M.</au><au>O'Duffy, Fergal</au><au>White-Gibson, Ailbhe</au><au>O'Neill, Paul</au><au>Kinsella, John</au><au>Timon, Conrad</au><au>Lennon, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Supporting the use of adjuvant radiotherapy in recurrent pleomorphic adenoma of the parotid</atitle><jtitle>Acta oto-laryngologica</jtitle><addtitle>Acta Otolaryngol</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>141</volume><issue>10</issue><spage>971</spage><epage>976</epage><pages>971-976</pages><issn>0001-6489</issn><eissn>1651-2251</eissn><abstract>The use of adjuvant radiotherapy remains controversial in the treatment of recurrent pleomorphic adenomas.
The aim of this study was to provide the highest level of evidence possible by performing a systematic review and meta-analysis of the literature.
We searched the English-language literature between 1985 and 2019.Inclusion criteria included any study on the treatment and outcome of recurrent pleomorphic adenomas. Exclusion criteria included the use of radiotherapy for residual tumors, case reports, and pleomorphic adenomas not arising from the parotid.
A total of 522 abstracts were studied, data analyzed from 14 studies, on a total of 697 patients. When the data werepooled, the overall risk of further recurrence was 21%. In studies where surgery alone was undertaken this increased to 26% and decreased to 10% in those receiving adjuvant radiotherapy (p = .000). There were 21 recurrences in 159 patients in the radiotherapy group, and 151 recurrences out of 538 patients in the surgery group (p < .0001).
These data support the use of radiotherapy to decrease the risk of re-recurrence in recurrent pleomorphic adenoma.
This study is the highest level of evidence currently available in guiding management of recurrent pleomorphic adenoma.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>34622733</pmid><doi>10.1080/00016489.2021.1980226</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7837-4032</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6489 |
| ispartof | Acta oto-laryngologica, 2021-10, Vol.141 (10), p.971-976 |
| issn | 0001-6489 1651-2251 |
| language | eng |
| recordid | cdi_pubmed_primary_34622733 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adenoma, Pleomorphic - therapy Humans meta-analysis Neoplasm Recurrence, Local - therapy Parotid Neoplasms - therapy Pleomorphic adenoma radiotherapy Radiotherapy, Adjuvant recurrent Secondary Prevention |
| title | Supporting the use of adjuvant radiotherapy in recurrent pleomorphic adenoma of the parotid |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A28%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Supporting%20the%20use%20of%20adjuvant%20radiotherapy%20in%20recurrent%20pleomorphic%20adenoma%20of%20the%20parotid&rft.jtitle=Acta%20oto-laryngologica&rft.au=Hintze,%20Justin%20M.&rft.date=2021-10-01&rft.volume=141&rft.issue=10&rft.spage=971&rft.epage=976&rft.pages=971-976&rft.issn=0001-6489&rft.eissn=1651-2251&rft_id=info:doi/10.1080/00016489.2021.1980226&rft_dat=%3Cproquest_pubme%3E2580694666%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-1c1460ecf4fbc638012c9359c7fdcc839eb80f85491079b7b5d8349b8ec7264a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2580694666&rft_id=info:pmid/34622733&rfr_iscdi=true |